Use of ultrarapid acting insulin
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
1. A method of avoiding body weight gain in an overweight patient with diabetes currently using a prandial injected insulin, said method comprising replacing said prandial injected insulin with an inhaled formulation comprising a recombinant human insulin and a diketopiperazine, and further comprising administering a post-prandial dose of the inhaled formulation if blood glucose levels exceed 140 mg/dL at 60 to 120 minutes after the meal.
2. The method of claim 1 , wherein the inhaled formulation comprises 3,6-di(fumaryl-4-aminobutyl)-2,5-diketopiperazine.
3. The method of claim 2 , wherein the inhaled formulation comprises an insulin dosage of up to 32 units.
4. The method of claim 3 , wherein the inhaled formulation is administered using a dry powder inhaler.
5. The method of claim 4 , further comprising administration of a long-acting insulin analog within 6 hours of waking.
6. The method of claim 5 , wherein the administration of the long acting insulin analog is within 3 hours of waking.
7. The method of claim 5 , wherein the long acting insulin analog is insulin detemir or insulin glargine.
8. The method of claim 7 , wherein said patient has diabetes mellitus.
9. The method of claim 8 , wherein said diabetes mellitus comprises diabetes type 2.
10. The method of claim 1 , further comprising determination of the patient's dosage by identifying the meal resulting in the highest 2-hour post-prandial blood glucose levels using 7 point SMBG (serum measured blood glucose), and titrating up the dosage for that meal.
11. The method of claim 10 , wherein said meal comprises one of breakfast, lunch, dinner, or regularly occurring snack.